Moneycontrol Be a Pro
Get App
Last Updated : Sep 12, 2019 02:48 PM IST | Source:

Granules India jumps 6% on Establishment Inspection Report from USFDA for Bonthapally unit

Bonthapally facility is one of the world's largest single site Paracetamol API manufacturing plant by volume.

Moneycontrol News @moneycontrolcom
Representative image
Representative image
  • bselive
  • nselive
Todays L/H

Shares of Granules India rallied 6 percent intraday on September 12 after receiving Establishment Inspection Report from the US health regulator for Bonthapally unit.

The stock rallied 15 percent in the last three sessions. It was quoting at Rs 104.40, up Rs 5.40, or 5.45 percent on the BSE at 1440 hours IST.

The US Food and Drug Administration has issued an Establishment Inspection Report (EIR) for the company's Bonthapally facility, Hyderabad.


This facility was inspected by the USFDA in July 2019 and there was one (1) observation during the inspection, the company in its BSE filing said.

Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plant by volume, it added.

Along with Paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, it said.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Sep 12, 2019 02:48 pm
Follow us on
Available On
PCI DSS Compliant